These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3943929)

  • 1. Measurement of plasma disopyramide as a guide to paediatric use.
    Baker EJ; Hayler AM; Curry PV; Tynan M; Holt DW
    Int J Cardiol; 1986 Jan; 10(1):65-9. PubMed ID: 3943929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiarrhythmic action of disopyramide: a study of plasma levels].
    Page A; Pic A; Besse P
    Arch Mal Coeur Vaiss; 1979 Jul; 72(7):774-80. PubMed ID: 117775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute oral antiarrhythmic testing with disopyramide.
    García-Barreto D; Toruncha A; Gonzalez-Gomez A; Llerena L; Groning E; Hernandez-Cañero A
    Clin Cardiol; 1981; 4(6):330-5. PubMed ID: 7326884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study.
    Caron JF; Libersa CC; Kher AR; Kacet S; Wanszelbaum H; Dupuis BA; Poirier JM; Lekieffre JP
    J Am Coll Cardiol; 1985 Jun; 5(6):1457-63. PubMed ID: 2582017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial.
    Sbarbaro JA; Rawling DA; Fozzard HA
    Am J Cardiol; 1979 Sep; 44(3):513-20. PubMed ID: 474432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentration of disopyramide given as capsules and controlled release tablets.
    Arnman K; Graffner C; Rikner L; Ryden L; Voog L
    Eur J Clin Pharmacol; 1983; 24(2):199-203. PubMed ID: 6840167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias.
    Arif M; Laidlaw JC; Oshrain C; Willis PW; Nissen CH; McDermott DJ; Smith WS; Karim A; Wilson RR
    Angiology; 1983 Jun; 34(6):393-400. PubMed ID: 6408949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of disopyramide after administration of conventional capsules and sustained-release tablets.
    Nauta IL; van de Calseyde J; Hertzberger DP
    Curr Med Res Opin; 1983; 8(8):582-93. PubMed ID: 6653136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
    Deano DA; Wu D; Mautner RK; Sherman RH; Ehsani AI; Rosen KM
    Chest; 1977 May; 71(5):597-606. PubMed ID: 856558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum disopyramide concentrations and suppression of ventricular premature contractions.
    Ueda CT; Dzindzio BS; Vosik WM
    Clin Pharmacol Ther; 1984 Sep; 36(3):326-36. PubMed ID: 6467792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of disopyramide and mexiletine for better tolerance and additive effects for treatment of ventricular arrhythmias.
    Kim SG; Mercando AD; Tam S; Fisher JD
    J Am Coll Cardiol; 1989 Mar; 13(3):659-64. PubMed ID: 2918173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disopyramide: serum level and arrhythmia conversion.
    Niarchos AP
    Am Heart J; 1976 Jul; 92(1):57-64. PubMed ID: 785988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease.
    Tanabe T; Takahashi K; Yoshioka K; Goto Y
    Int J Cardiol; 1991 Sep; 32(3):303-12. PubMed ID: 1724233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disopyramide kinetics in patients with acute myocardial infarction.
    Ilett KF; Madsen BW; Woods JD
    Clin Pharmacol Ther; 1979 Jul; 26(1):1-7. PubMed ID: 445953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of and adverse effects of disopyramide. Comparison of capsules, controlled release tablets and placebo in patients with chronic ventricular arrhythmias.
    Ekelund LG; Nilsson E; Walldius G
    Eur J Clin Pharmacol; 1986; 29(6):673-7. PubMed ID: 3519236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias.
    Capparelli EV; DiPersio DM; Zhao H; Kluger J; Chow MS
    J Clin Pharmacol; 1988 Apr; 28(4):306-11. PubMed ID: 3392228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low oral doses of disopyramide and amiodarone on ventricular and atrial arrhythmias of chagasic patients with advanced myocardial damage.
    Carrasco HA; Vicuña AV; Molina C; Landaeta A; Reynosa J; Vicuña N; Fuenmayor A; López F
    Int J Cardiol; 1985 Dec; 9(4):425-38. PubMed ID: 3908329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of intravenous disopyramide in acute cardiac arrhythmias.
    De Backer M; Stoupel E; Kahn RJ
    Eur J Clin Pharmacol; 1981 Jan; 19(1):11-8. PubMed ID: 6161824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of disopyramide in resistant cardiac arrhythmias due to acute ischaemic heart disease.
    Sandler G
    J Int Med Res; 1977; 5(5):369-73. PubMed ID: 913864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.